Solventum Corporation (NYSE:SOLV) Receives Average Rating of “Moderate Buy” from Brokerages

Solventum Corporation (NYSE:SOLV) has been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $84.25.

Several research firms have recently issued reports on SOLV. Piper Sandler lowered their price objective on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. KeyCorp raised their price objective on Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Weiss Ratings raised Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 11th. Finally, Wedbush began coverage on Solventum in a research note on Friday, May 15th. They issued an “outperform” rating and a $94.00 price objective for the company.

Institutional Investors Weigh In On Solventum

Several institutional investors have recently modified their holdings of SOLV. Hilltop National Bank raised its holdings in shares of Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after buying an additional 129 shares during the period. CrossGen Wealth LLC purchased a new stake in shares of Solventum in the fourth quarter worth approximately $25,000. Measured Wealth Private Client Group LLC purchased a new stake in shares of Solventum in the third quarter worth approximately $25,000. Clearstead Trust LLC raised its holdings in shares of Solventum by 61.0% in the first quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock worth $26,000 after buying an additional 150 shares during the period. Finally, JNBA Financial Advisors raised its holdings in shares of Solventum by 205.4% in the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock worth $27,000 after buying an additional 228 shares during the period.

Solventum Price Performance

Shares of Solventum stock opened at $75.72 on Friday. The firm has a market cap of $13.11 billion, a PE ratio of 9.28, a PEG ratio of 1.15 and a beta of 0.69. Solventum has a 12 month low of $62.38 and a 12 month high of $88.20. The stock has a 50 day moving average of $73.51 and a 200 day moving average of $74.94. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.13. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same period last year, the company earned $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, research analysts expect that Solventum will post 6.58 EPS for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.